Literature DB >> 16042907

Diagnosis and treatment of irritable bowel syndrome: state of the art.

Kirsten Tillisch1, Lin Chang.   

Abstract

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with a wide variety of presentations that may include abdominal pain, bloating, diarrhea, constipation, or alternating bowel habits. Symptom-based criteria and a limited medical evaluation are used for diagnosis. The heterogeneity of IBS presenting symptoms, together with the pathophysiology of the disorder, is unclear, making treatment challenging. Treatment strategies are focused on specific symptoms, potential underlying disorders in stress responsiveness, and predisposing psychological features. Although only two medications, tegaserod for constipation-predominant IBS and alosetron for diarrhea-predominant IBS, are specifically indicated, a wide variety of treatment options are available and are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042907     DOI: 10.1007/s11894-005-0016-y

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  56 in total

1.  Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.

Authors:  G Tougas; W J Snape; M H Otten; D L Earnest; K-E Langaker; R E Pruitt; E Pecher; B Nault; M A Rojavin
Journal:  Aliment Pharmacol Ther       Date:  2002-10       Impact factor: 8.171

2.  Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.

Authors:  A Madisch; G Holtmann; K Plein; J Hotz
Journal:  Aliment Pharmacol Ther       Date:  2004-02-01       Impact factor: 8.171

3.  Costs of care for irritable bowel syndrome patients in a health maintenance organization.

Authors:  R L Levy; M Von Korff; W E Whitehead; P Stang; K Saunders; P Jhingran; V Barghout; A D Feld
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

4.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

Review 5.  A review of the evidence for overlap among unexplained clinical conditions.

Authors:  L A Aaron; D Buchwald
Journal:  Ann Intern Med       Date:  2001-05-01       Impact factor: 25.391

6.  Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

Authors:  K R Neal; L Barker; R C Spiller
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

7.  Acupuncture has a placebo effect on rectal perception but not on distensibility and spatial summation: a study in health and IBS.

Authors:  Reingard B K Rohrböck; Johann Hammer; Harald Vogelsang; Nicholas J Talley; Heinz F Hammer
Journal:  Am J Gastroenterol       Date:  2004-10       Impact factor: 10.864

8.  The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.

Authors:  Francis Creed; Lakshmi Fernandes; Elspeth Guthrie; Stephen Palmer; Joy Ratcliffe; Nicholas Read; Christine Rigby; David Thompson; Barbara Tomenson
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

9.  An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.

Authors:  J Kellow; O Y Lee; F Y Chang; S Thongsawat; M Z Mazlam; H Yuen; K A Gwee; Y T Bak; J Jones; A Wagner
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

10.  Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial.

Authors:  Gary Tabas; Mary Beaves; Jiping Wang; Paul Friday; Houssam Mardini; George Arnold
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

View more
  10 in total

1.  Common component classification: what can we learn from machine learning?

Authors:  Ariana Anderson; Jennifer S Labus; Eduardo P Vianna; Emeran A Mayer; Mark S Cohen
Journal:  Neuroimage       Date:  2010-06-25       Impact factor: 6.556

Review 2.  Irritable bowel syndrome and chronic constipation: emerging drugs, devices, and surgical treatments.

Authors:  Lucinda A Harris; Stephanie Hansel; John DiBaise; Michael D Crowell
Journal:  Curr Gastroenterol Rep       Date:  2006-08

3.  Analgesic effects of JCM-16021 on neonatal maternal separation-induced visceral pain in rats.

Authors:  Zhao-Xiang Bian; Man Zhang; Quan-Bin Han; Hong-Xi Xu; Joseph J Y Sung
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

Review 4.  Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.

Authors:  Paula Mosińska; Jakub Fichna; Martin Storr
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 5.  Psychosocial impact of irritable bowel syndrome: A brief review.

Authors:  Sarah Ballou; Alyse Bedell; Laurie Keefer
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

6.  Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea.

Authors:  Mary E Money; Jaroslaw Walkowiak; Chris Virgilio; Nicholas J Talley
Journal:  Frontline Gastroenterol       Date:  2010-11-03

7.  The potential role of probiotics in the management of childhood autism spectrum disorders.

Authors:  J William Critchfield; Saskia van Hemert; Michael Ash; Linda Mulder; Paul Ashwood
Journal:  Gastroenterol Res Pract       Date:  2011-10-26       Impact factor: 2.260

8.  The gut microbiota and irritable bowel syndrome: friend or foe?

Authors:  Uday C Ghoshal; Ratnakar Shukla; Ujjala Ghoshal; Kok-Ann Gwee; Siew C Ng; Eamonn M M Quigley
Journal:  Int J Inflam       Date:  2012-04-22

9.  Variation in Care for Patients with Irritable Bowel Syndrome in the United States.

Authors:  Brian E Lacy; Haridarshan Patel; Annie Guérin; Katherine Dea; Justin L Scopel; Reza Alaghband; Eric Qiong Wu; Reema Mody
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

10.  The Impact of an Individual Educational Program on the Quality of Life and Severity of Symptoms of Patients with Irritable Bowel Syndrome.

Authors:  Regina Sierżantowicz; Jolanta Lewko; Grażyna Jurkowska
Journal:  Int J Environ Res Public Health       Date:  2020-06-13       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.